C12N 15/113
Non-coding nucleic acids modulating the expression of genes
Official title: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
C12N15/113 (Non-coding nucleic acids modulating the expression of genes) appears on 13,160 US grants and 25,859 published applications in this corpus.
Search patents in C12N- Granted patents
- 13,160
- Published applications
- 25,859
- Assignees
- 5,189
- Inventors
- 33,340
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 5 | 0 |
| 1992 | 13 | 0 |
| 1993 | 28 | 0 |
| 1994 | 22 | 0 |
| 1995 | 31 | 0 |
| 1996 | 66 | 0 |
| 1997 | 155 | 0 |
| 1998 | 193 | 0 |
| 1999 | 213 | 0 |
| 2000 | 239 | 0 |
| 2001 | 197 | 41 |
| 2002 | 194 | 169 |
| 2003 | 127 | 521 |
| 2004 | 113 | 511 |
| 2005 | 60 | 474 |
| 2006 | 100 | 381 |
| 2007 | 91 | 492 |
| 2008 | 98 | 437 |
| 2009 | 178 | 709 |
| 2010 | 317 | 779 |
| 2011 | 329 | 778 |
| 2012 | 447 | 795 |
| 2013 | 461 | 862 |
| 2014 | 574 | 1032 |
| 2015 | 649 | 1188 |
| 2016 | 670 | 1242 |
| 2017 | 742 | 1150 |
| 2018 | 773 | 1257 |
| 2019 | 800 | 1428 |
| 2020 | 778 | 1494 |
| 2021 | 822 | 1659 |
| 2022 | 802 | 1705 |
| 2023 | 734 | 1708 |
| 2024 | 746 | 1890 |
| 2025 | 777 | 1824 |
| 2026 | 611 | 1333 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Pharmaceutical composition containing anionic drug, and preparation method therefor6 Oct 2026US 12,752,010 B2Samyang Holdings Corporation
- ß-amyloid cyclic ribonucleic acid, polypeptide, and application thereof6 Oct 2026US 12,753,215 B2
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- CAS12B enzymes and systems6 Oct 2026US 12,753,406 B2Massachusetts Institute of Technology
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- Methods and compositions for microbial delivery of double stranded rna8 Oct 2026US 2026/0305618 A1Rnaissance AG LLC
- Composition and Method for Topical Trans-spinal Delivery of Nucleic Acids and Small Molecules8 Oct 2026US 2026/0306414 A13P Biotechnologies, Inc.
- Modified adeno-associated virus vector and use thereof in treating neurological diseases8 Oct 2026US 2026/0306673 A1Genecombio Ltd.
- Extracellular vesicles8 Oct 2026US 2026/0308526 A1VivaZome Therapeutics Pty Ltd
- Engineered compact crispr-cas12f system8 Oct 2026US 2026/0308554 A1
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Peptide nucleic acids763US 5,539,082 A1996